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The Role of the DNA Damage 
Response in Ataxia-Telangiectasia 
Syndrome
Albert Ribes-Zamora
Abstract
The DNA damage response (DDR) is a concerted response involving a myriad 
of pathways that cells elicit in the presence of DNA injuries. Patients bearing 
mutations in DDR genes have an increased cancer incidence derived from their 
diminished ability to respond to DNA damage, and the consequent increase in 
mutations. Intriguingly, mutations in ATM, the chief DDR regulator, can cause 
ataxia telangiectasia, a neurodegenerative disorder characterized by progressive 
loss of movement coordination, weak immune system, and increased cancer risk. 
The relationship between ATM and neural system development and degeneration 
remains to be fully elucidated and will be discussed in this chapter.
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1. Introduction
Mammalian cells face an estimate of 105 genomic injuries every day. These lesions 
are diverse and can include, among others, single (SSB) and double strand breaks 
(DSB), oxidative damage, DNA inter- and intra-strand crosslinking, base mis-
matches, bulky adducts, and photoproducts [1, 2]. This large variety of DNA lesions is 
directly related to the full range of mutation-causing agents that threaten the genome 
on a daily basis. Some of these agents are endogenously produced by the cell’s own 
metabolism and homeostasis, while others are generated exogenously. The frequency 
of appearance of these lesions is also diverse, and it may depend on the cell type or the 
developmental stage [1]. For instance, skin epithelial cells are much more susceptible 
to photoproducts caused by ultraviolet rays, an exogenous source of mutations that 
can only reach the outermost layers of our body. In contrast, reactive oxygen species 
(ROS) are endogenous metabolic byproducts that can induce oxidative base modifica-
tions and SSB, one of the most common genomic injuries. Cells with high energy and 
metabolic demands are, therefore, most susceptible to suffer SSB-related and other 
ROS-related injuries.
To defend from the menacing threat that this wide range and number of lesions 
pose to the integrity of their genome, cells can invoke the DNA damage response 
(DDR), a vast network of overlapping pathways that is capable of tailoring a 
response depending on the type and extent of the lesion and the cell cycle stage at 
the moment of the injury [3–6]. DDR requires the coordination of DNA repair path-
ways with cell cycle progression regulation, transcription activation, and apoptosis, 
among other pathways [5, 7, 8].
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Somewhat surprisingly, mutations in genes belonging to DDR pathways corre-
late with neurodevelopmental defects and neurodegenerative pathologies [5, 9–11]. 
For instance, individuals with dysfunctional versions of SSB repair genes APTX, 
PNPK, or XRCC1 manifest different types of ataxias with ocular apraxia; whereas, 
defective TDP1, also involved in SSB repair, can cause spinocerebellar ataxia with 
axonal neuropathy [9, 12]. Similarly, mutations in DSB repair gene MRE11, or 
central DDR regulators ATM and ATR, can lead to cerebellar ataxia [5, 13]. Besides 
ataxias, microcephaly is commonly found linked to defects in several DDR associ-
ated genes [1, 5, 14]. Mutations in NBS1 and RAD50, two genes involved in end 
processing during DSB repair, can cause Nijmegen breakage syndrome (NBS) 
and NBS-like syndrome, respectively, both syndromes manifesting microcephaly 
among other conditions [5, 15, 16]. Microcephalia is also present in individuals with 
dysfunctional PNPK, LIG4—a gene involved in DSB repair—or Seckel Syndrome 
1, a developmental disorder caused by some ATR mutations [9, 15]. Furthermore, 
around 25% of patients with defective nucleotide excision repair (NER)—a DDR 
pathway in charge of healing photoproducts created by UV light exposure—can 
also present microcephaly among other neurological problems [5]. Overall, this 
data suggest a strong and intriguing link between DDR, neurodevelopment, and 
neuropathology. This review focuses on ATM, its role during DDR, and the molecu-
lar basis of ataxia-telangiectasia (A-T), a neurodegenerative syndrome caused by 
defective or absent ATM.
2. ATM roles during DDR
ATM and ATR are two kinases belonging to the protein phosphatidylinositol-
3-kinase-like kinases (PIKK) family that function as the chief regulators of DDR 
[3, 11, 13]. Together, they coordinate all pathways implicated in DDR to offer an 
adequate and timely response proportionate to the type and extent of the genomic 
injury. Recently, DNA-PKcs, another member of the PIKK family, has also been 
found playing more substantial roles in regulating DDR than initially thought, 
albeit to a lesser extent that ATM and ATR [17].
ATM is a very large kinase of 3056 amino acids and a molecular weight of 
350.6 kD that resides in the nucleus as inactive homodimers. Upon DNA dam-
age infliction, phosphorylation of a critical ATM residue disrupts dimerization, 
prompting monomers to undergo further phosphorylation to achieve full kinase 
activation [18–20]. Active ATM monomers phosphorylate substrates on serine or 
threonine residues followed by glutamine (S/TQ ), and a significant amount of 
ATM substrates contain clusters of S/TQ sites in short stretches of the protein [21]. 
These so-called SCD domains can be used to mine the proteome for putative ATM 
targets [22–24]. Using mass spectrometry, a high-throughput screen for proteins 
phosphorylated following DNA damage found 686 putative DDR targets and the 
final number is estimated to surpass a thousand proteins [25]. These large numbers 
showcase the complexity of DDR, and the need for an orchestrated coordination of 
all pathways involved. Some of the most important direct ATM targets are CHK2 
and p53, two downstream effectors that modulate pivotal DDR pathways like cell 
cycle progression regulation, DNA repair, or apoptosis [26–28].
2.1 DNA repair
ATM is not only activated by different kinds of DNA damage but can also 
actively participate in several DNA repair mechanisms and coordinate their 
activities with other DDR-related pathways [7, 29]. During DSB repair, ATM 
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plays crucial roles in the early end-processing events, signal amplification, and 
recruitment of other DNA repair proteins to the sites of damage [3, 13]. ATM 
functions in homologous recombination (HR) and nonhomologous end-joining 
(NHEJ), the two pathways entrusted by cells to repair DSBs. Whereas, NHEJ is 
active throughout the cell cycle, its function is mostly limited to G0/G1 as S/G2 
phases prefer the more accurate HR, a mechanism that uses sister chromatids only 
present during those phases as repair templates. The first sensor of DSBs is PARP1, 
which in addition to binding breaks, also adds branches of poly-(ADP)-ribose to 
proteins post-translationally [30]. This so-called PARylation process activates and 
recruits several DNA repair proteins to the sites of damage [31]. One of them is the 
MRN complex—made up of MRE11, RAD50, and NBS1—that binds and activates 
ATM [32, 33]. Interaction with PARP1 and NBS1, thus, activates and recruits ATM 
to DSB sites, where it phosphorylates several downstream targets and effectors to 
amplify DDR signaling. For instance, ATM phosphorylates histone variant H2AX, 
which promotes MDC1 binding to the chromatin surrounding DSB [34–36]. Once 
there, ATM-mediated phosphorylation of MDC1 promotes its binding to MRN, and 
recruitment of more ATM to phosphorylate more H2AX, further spreading DDR 
signaling [13].
Although the complete process remains to be fully elucidated, it is clear that 
ATM is also involved in the decision-making process that selects either HR or NHEJ 
to repair a DSB [37, 38]. A crucial step in this process is the extent of end resec-
tion that takes place at DSB [39]. ATM directly phosphorylates CtIP and BRCA1, 
two HR proteins required for resection initiation and binding of RAD51 to ssDNA 
ends, respectively [40–42]. Once formed, RAD51 coated 3′ ssDNA ends steer repair 
toward HR by initiating strand invasion into the sister chromatid. Intriguingly, 
ATM phosphorylates p53BP1 and promotes its recruitment to sites of DNA damage 
[43]. Phosphorylated p53BP1 has opposing roles to CtIP and BRCA1, and favors the 
formation of p53BP1 containing complexes at DSB that counteract HR in favor of 
NHEJ repair [38, 44]. ATM also influences NHEJ by mediating DNA-PKcs phos-
phorylation and subsequent recruitment of Artemis, an end-processing nuclease, to 
DSB sites [45].
Although ATM is mostly activated by DSBs, recent data suggest that some 
lesions that are usually repaired by BER can also activate ATM and that ATM-
dependent phosphorylation events can regulate BER [46]. Following base damage, 
BER requires the sequential action of DNA glycosylases—to remove damaged bases 
and create apyrimidinic or apurinic (AP) sites, PARP1—to PARylate the AP site, 
and endonucleases that will generate an SSB at the AP site [47]. These events can 
lead to ATM activation and the ATM-dependent phosphorylation of CHK2 [46]. 
Upon activation, CHK2 phosphorylates XRCC1, a BER protein required for sealing 
the nick and completing the repair.
DDR is capable of modulating DNA repair pathways through multiple effectors. 
For instance, both ATR and p53 regulate NER through quite distinct mechanisms. 
While ATR phosphorylates XPA, one of the earliest respondents to pyrimidine 
photodimers and other bulky lesions, DDR-dependent phosphorylation of p53 acts 
by upregulating expression of NER genes and recruiting XPC and TFIIH to sites of 
damage [7, 48–52]. ATR also regulates ICLR through the phosphorylation of several 
members of the Fanconi anemia group, a set of proteins that in combination with 
NER and HR, repair DNA cross-linkage damage [53–55]. Other examples of DDR-
signaling-dependent regulation of DNA repair mechanisms include the upregula-
tion of BER through the stimulatory binding of p53 to BER proteins, the promotion 
of HR that ensues after disruption of the p53-RPA complex by ATM, ATR and 
DNA-PKcs phosphorylation, and the PIKK-dependent phosphorylation of Werner 
syndrome and Bloom syndrome proteins involved in DSB repair [56–60].
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2.2 Cell cycle progression regulation
One of the most dangerous threats of DNA damage is the possibility of spread-
ing to daughter cells during cell duplication. To prevent this, DDR is capable of 
halting cell cycle progression at any point during the cell cycle [61]. A series of 
overlapping mechanisms ensure that cells attempt DNA repair before progressing to 
the next cell cycle stage [7].
ATM is in charge of preventing lesions produced during G1/G0 to enter S phase, 
which is particularly important for some of the most common DNA injuries like 
oxidative damage. Since G1/G0 duration is usually longer than other cell cycle phases, 
exposure to ROS and other mutating agents is also higher in these stages, and so is the 
appearance of related damage. ATM acts in conjunction with CHK2 and p53 to block 
G1/S transition by inhibiting CDK2, the cycle-dependent kinase that along with 
Cyclin E, triggers S-phase entry [62]. CDK2 inhibition is achieved by two overlapping 
mechanisms that have ATM at their apex. On one hand, ATM phosphorylation of 
CHK2 triggers phosphorylation of CDC25A, a phosphatase required for CDK2 activa-
tion and promoting entry into S-phase [63, 64]. On the other hand, ATM-dependent 
activation of p53 induces upregulation of p21, which acts as a CDK2 inhibitor [65].
Replicative stresses during S-phase trigger the activation of the Intra-S-phase 
checkpoint to ensure that replicative stress and other types of damages do not 
persist in the following cell cycle stages. ATR, not ATM, is the PIKK responsible for 
halting the cell cycle at this stage through the activation of the intra-S-phase [61]. 
During this checkpoint ATR, CHK1, and p53 act together and in overlapping ways 
to phosphorylate CDK2, which renders it unable to form an active CDK2/cyclin A 
complex [63, 66]. The final result is DNA synthesis termination, premature stalling, 
and subsequent halt of the cell cycle.
The concerted action of ATR, CHK1, and p53 also controls the G2/M transition to 
ensure that no cell enters mitosis with lingering DNA damage from previous phases 
[67–69]. The importance of this checkpoint is highlighted by the presence of multiple 
overlapping and complementary mechanisms actively working together to inhibit 
CDK1/CyclinB1, the complex required to trigger entry into mitosis [66]. CDK1 phos-
phorylation has an inhibitory effect and thus, is the primary target of several of these 
mechanisms. After ATR-mediated activation, CHK1 phosphorylates CDC25C, a phos-
phatase required for CDK1 activation. Phosphorylated CDC25C binds to the 14-3-3 
complex, which promotes its transport to the cytoplasm, effectively preventing CDK1 
activation [70]. Active CHK1 also phosphorylates and activates WEE1, a kinase that 
promotes inhibitory phosphorylation of CDK1 [71]. Furthermore, ATR phosphory-
lates PLK1 and inhibits its role as WEE1 inhibitor, while p53 upregulates GADD45, 
which binds and further inhibits CDK1/CyclinB1 complex [72, 73]. Importantly, ATM 
also play roles in this combined effort to keep CDK1/CyclinB1 inhibited, as it can 
phosphorylate PLK1 and promote CHK1-mediated CDC25C phosphorylation [73, 74].
Finally, the Intra-M checkpoint is the last opportunity to prevent the transmis-
sion of damage to daughter cells. ATM and CHK1 govern this checkpoint through 
two distinct mechanisms that act sequentially during mitosis progression. First, 
inhibitory phosphorylation of PLK1 by CHK1 prevents it from acting during spindle 
formation and halts the cell cycle [74]. At a later point, ATR-mediated phosphory-
lation of Aurora B stimulates the inhibitory effect that this enzyme exerts over 
cytokinesis and delays exits of mitosis if the damage is detected [75].
2.3 Transcription regulation
Activation of DDR induces substantial changes to the transcriptome to equip cells 
with necessary tools and time to articulate a proper response. While the overall effect 
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of DDR activation is an attenuation of global transcription and translation, many 
genes involved in DDR pathways must be upregulated instead [76]. For example, 
upregulation of XPC and other NER genes follows DDR activation, and as previously 
noted, DDR-mediated blocking of cell cycle progression is dependent on the induc-
tion of certain genes, namely p21 [77]. DDR exerts its influence on gene transcrip-
tion through the action of several transcription factors that act as downstream 
effectors of DDR signaling. Some of the most important examples are p53 and 
BRAC1, AP-1, or E2F1. For instance, BRAC1 and p53 upregulate XPC during DDR-
mediated NER upregulation; whereas, AP-1 induces the expression of XPF and XPG 
during the same process [76]. Other examples are p53 and AP-1 serving as transcrip-
tion factors for MLH1 and MSH2—two mismatch repair genes—and E2F1 and AP-1 
influencing the expression of BER components XRCC1 and APEX1, respectively.
2.4 Apoptosis and senescence
Paramount for DDR is its ability to trigger apoptosis when DNA damage is too 
extensive and incompatible with genome stability. Both ATM and ATR can promote 
apoptosis through the phosphorylation of p53, the chief regulator of apoptosis dur-
ing DDR [78–80]. p53 can trigger apoptosis by playing dual roles as transcription 
factor activator and anti-apoptotic protein inhibitor. In the presence of unrepairable 
damage, p53 upregulates pro-apoptotic genes like PUMA or BAX, while binding 
and inhibiting anti-apoptotic proteins like BCL2 [81, 82]. In addition to apoptosis, 
extensive DNA damage can also induce senescence, a metabolic state that causes 
irreversible growth arrest [83]. Among other mechanisms, senescence can be 
induced during DDR by ATM and p53 upregulation of p21 [84].
2.5 Other DDR pathways
ATM and ATR also integrate into DDR several other pathways that are essential 
to provide an adequate and proportionate response to all kind of injuries. For 
instance, no proper DDR can occur without the upregulation of dNTP for DNA 
repair [85]. This upregulation requires tight control, as excessive dNTP production 
can lead to increased mutation frequency [86]. In the presence of DNA damage, 
DDR kinases regulate RNR—the kinase that catalyzes rate-limiting step during 
dNTP production—at multiple levels. For instance, p53 regulates the expression 
levels of RNR; whereas, ATM phosphorylation increases the stability of RNR [87]. 
In addition, ATR signaling inhibits degradation of some RNR subunits, further 
contributing to the regulation of dNTP levels by DDR kinases.
Dysfunctional telomeres can also activate ATM and ATR and elicit a response 
that includes halting the cell cycle and induction of senescence [88]. Telomere 
dysfunction can arise when errors in the Shelterin complex render telomeres 
unprotected. Loss of protection at telomeres can also occur by the natural attrition 
of telomere length experienced during DNA replication in cells that do not express 
telomerase [89]. In both cases, DNA ends at telomeres can be mistakenly recognized 
as DNA damage events and activate DDR.
Recently, activation of autophagy has emerged as another tool that DDR can 
use to fight severe DNA damage. While autophagy was initially thought to be 
exclusively activated in response to cellular damage or starvation, there is clear 
evidence that DNA damage can also trigger autophagy [90]. For instance, the 
action of mTOR—the main autophagy inhibitor—can be repressed either in an 
ATM or PARP1 dependent manner following DNA damage, effectively promoting 
autophagy [7]. Consistent with this, in response to ROS mediated damage, ATM 
can induce selective degradation of mitochondria by autophagy (also known as 
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mitophagy) and pexophagy—the autophagic degradation of peroxisomes [91–93]. 
Integration of autophagy pathways as part of DDR repertoire may allow cells in 
stress to attempt pro-survival pathways first before succumbing to apoptosis.
While the complex relationships between DDR and inflammation are beginning 
to emerge, it is clear that ROS and other types of genomic injuries can elicit a pro-
inflammatory response. As part of DDR, this pro-survival cell response is mediated 
mostly through ATM and PARP1 [94]. ATM directly binds and phosphorylates IKK-γ 
(NEMO), the regulatory subunit of the IKK complex that activates NF-kB [41]. Along 
with PARP1-mediated post-translational modifications, ATM phosphorylation of IKK-γ 
promotes activation of IKK and subsequent activation of NF-kB [41, 95–97]. Therefore, 
this critical pro-inflammatory enzyme is under DDR control, where it can function 
as a transcription factor promoting expression of pro-inflammatory cytokines and 
DNA repair genes [76, 94, 95, 98]. In addition, ATM is involved in a pro-inflammatory 
pathway known as senescence-associated secretory phenotype (SASP), a complex 
mechanism that secretes, among others, pro-inflammatory cytokines [94, 99].
3. Molecular basis for ataxia telangiectasia syndrome
A-T is an autosomal recessive genetic disease that affects 1 in every 40,000–100,00 
births with an estimated 0.5–1% of the global population being carriers of the illness 
[100]. Patients confront a variety of clinical manifestations throughout their lives, 
with the inability to control body movements, or ataxia, being one the earliest to 
appear [101]. The underlying cause for the ataxia is progressive neurodegeneration, 
particularly of the cerebellum, which also induces dysarthria (speech difficulties), 
poor balance, and uncontrolled eye movements. Neurodegeneration involves the 
gradual disappearance of Purkinje, granular cells and the molecular layer of the 
cerebellar cortex, and expands to the brain stem and the spinal cord. A-T is also 
 characterized by the presence of vascular abnormalities (telangiectasia) that manifest 
as red spider-like veins, present mostly in the eyes, but also found in cheeks, ears, 
neck, and other parts of patients’ bodies [102, 103].
In addition to the ataxia and telangiectasia, A-T patients can suffer from a 
plethora of other clinical symptoms. They have a higher incidence of cancer, 
diabetes, and show premature aging. They manifest radiosensitivity, sterility, and 
immunodeficiencies with an elevated risk of developing autoimmune diseases 
such as arthritis, vitiligo, or immune thrombocytopenia [104]. Authors have also 
suggested that A-T patients may suffer from prolonged chronic inflammation [94]. 
Consistent with this, high levels of pro-inflammation cytokines are present in their 
serum even in the absence of infections [51, 52].
While mutations in other DDR gene can induce similar symptomatology, 
defective or absent, ATM is the sole genetic cause of A-T. Hundreds of pathogenic 
mutations have been identified in ATM from A-T patients, many of them altering 
splicing or causing frameshifts that result in premature termination codons. As a 
result, ATM is often either missing or containing truncations of different extents in 
A-T cells. Clinical manifestations correlate with the severity of the mutation, with 
milder forms of the syndrome appearing in individuals bearing mutations with 
mild effects on ATM function and vice versa [105].
3.1 Neurodegeneration
The most apparent clinical manifestation of the disease is probably also the most 
problematic to explain at the molecular level. The question of why mutations in a 
gene involved in DDR would have specific and discriminating effects in the neural 
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system remains to be fully answered [5, 106]. One of the problems in answering 
this question is that mouse models lacking functional ATM reconstitute most of the 
pleiotropic effects of A-T, except for neurodegeneration [107–109].
It is clear that during neurodevelopment, rapidly dividing cells—with high 
energetic demands and increased mitochondria respiration—face increasing 
levels of threats to the integrity of their genome [110, 111]. High metabolic rates 
increase ROS, and produce oxidative stress, which combined with the high demand 
for transcription, may render these cells more susceptible to faulty DNA repair 
mechanisms [110, 112]. This view is consistent with the high prevalence of neuro-
logical problems in patients bearing mutations in DNA repair genes [5, 9]. Authors 
have proposed a model where different stages during neurodevelopment are more 
susceptible to mutations in different DNA repair pathways, with HR having major 
roles during phases of rapid proliferation—when a sister chromatid is readily 
available—and NHEJ being required during late development when cells undergo 
differentiation in G1/G0 [9]. This would explain why mutations in HR often result 
in embryonic lethality; whereas, mutations in some NHEJ genes present neuro-
development problems such as microcephalia. In this model, single strand lesion 
repair would be required for post-developmental maintenance of neural tissue.
Cerebellum neurodegeneration in A-T patients also establishes ATM as a require-
ment to maintain neural tissue. The accumulation of unrepaired lesions during 
development—and beyond—results in degeneration problems later [113]. This is 
likely to happen at any tissue, but it would affect the neural system in particular, 
and with greater virulence, due to the longevity of its cells and the subsequent lon-
ger exposure to mutagenic agents. This injury build-up would occur progressively, 
mimicking the progressive nature of neurodegeneration in A-T patients.
Supporting this view, there are clear indications that neural A-T cells are under 
genotoxic stress. Mice cells lacking ATM gradually accumulate DSBs and show depleted 
levels of oxidized and reduced forms of NAD in cerebellar tissue, a hallmark of cells 
undergoing high levels of oxidative stress [114]. Interestingly, depletion of NAD levels 
only occurs in cerebellar tissues, but not in other parts of the brain, indicating that oxi-
dative stress may be particularly acute in the cerebellum. These data are consistent with 
other studies that found high levels of oxidative stress in the cerebellum and Purkinje 
cells in particular, which likely explains the higher prevalence of neurodegeneration in 
the cerebellum than in other parts of the neural system [115]. The reason for the local-
ized high levels of oxidative stress in cerebellar tissue compared to other regions of the 
neural system is not known, nor is the reason for the lack of a cerebellar degeneration 
phenotype in mice lacking ATM despite increased levels of oxidative damage.
These studies strongly suggest that the inability to repair damage caused by 
oxidative stress is the more plausible cause of cerebellar neurodegeneration in A-T 
and thus, the roles of ATM during the repair of single strand lesions may provide 
the molecular basis for the disease. The correlation between impaired single strand 
lesions repair and failure of neural tissue maintenance was further corroborated 
in mice that showed extensive neuron loss in the cerebellum when XRCC1 expres-
sion was selectively prevented in their brain [116]. While ATM mostly acts in DSB 
repair, it can also play roles during single strand lesion repair. As mentioned before, 
SSBs can activate ATM and promote BER by the ATM-mediated phosphorylation of 
XRCC1 (see Section 2.1) [46]. Whether or not, impairment of this DDR branch is 
related to the neurodegeneration observed in A-T remains to be elucidated.
Authors have also proposed that neurological problems arising in A-T patients 
may be related to the faulty resolution of R-loops in locations where active tran-
scription is halted due to the presence of DNA lesions [9, 13]. R-loops are hybrids 
formed by two strands of DNA and one of RNA that are generated in a variety 
of circumstances and locations and are known to pose a risk to genome stability 
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[117]. Paused RNA polymerase sites activate ATM, which then elicit a response that 
includes interactions with spliceosome components that may mediate R-loop resolu-
tion [118]. In the cerebellum, the combination of high levels of oxidative stress with 
high demands of transcription may produce an abnormally high amount of paused 
transcription sites due to DNA damage. In the absence of ATM, R-loops may not be 
adequately resolved, eventually creating a scenario incompatible with cell life.
3.2 Telangiectasia
The localized abnormal vascular formations that A-T patients show in several 
parts of their bodies—particularly in the eyes—is one of the most obvious and yet 
least investigated phenotypes of the disease [119]. Telangiectasia is highly preva-
lent in A-T, only missing in patients bearing mild ATM mutations that maintain 
some residual protein function [120]. Very little is known about the molecular 
mechanism that prompts telangiectasia when ATM is absent or dysfunctional. The 
current model proposes that oxidative stress caused by a lack of functional ATM 
may upregulate HIF1A levels, a hypoxia-activated transcription factor that can 
induce vascularization by increasing the levels of angiogenesis factor VEGF [120]. 
Intriguingly, SAPS also induces secretion of VEGF, suggesting a link between this 
DDR controlled pathway and vascularization [121, 122].
3.3 Immunodeficiency and inflammation
A-T patients can show low levels of at least one type of immunoglobulin, inad-
equate antibody responses to infections and abnormal T and B lymphocyte counts 
[123, 124]. These phenotypes can be attributed to the roles that ATM has in regulat-
ing NHEJ during V(D)J recombination and class-switch recombination (CSR), two 
recombination processes required to produce antibody diversity during adaptive 
immunity. Both V(D)J and CSR involve induction of programmed DSBs followed 
by ATM-aided NHEJ repair [125]. For instance, during V(D)J ATM localizes to 
break sites and regulate NHEJ components, while p53BP1 phosphorylation by ATM 
is a crucial event during CSR. The regulatory roles that ATM exerts on these two 
processes are likely to be extensive and involve other DDR pathways. In A-T patients 
with immunodeficiencies, programmed DSBs remain unrepaired, and their persis-
tence can cause severe T and B-cell developmental problems [126–128].
There is growing evidence that the innate immune response may be tightly linked 
to several clinical manifestations observed in A-T patients. Lack of ATM creates high 
levels of ROS and oxidative damage, which is known to induce pro-inflammatory cyto-
kines [111, 129, 130]. ATM-deficient cells cannot trigger pexophagy and other forms of 
autophagy to counteract the negatives effect of oxidative damage, further compound-
ing the problem [91]. Persistent genotoxic stress can, therefore, create chronic inflam-
mation in A-T patients, a condition linked to several A-T symptoms: increased levels 
of cardiovascular and autoimmune diseases, insulin resistance, and aging. Tellingly, 
the immune response contributes to neurodegeneration during Alzheimer’s disease, 
possibly suggesting that in A-T patients, chronic inflammation may also contribute to 
neurodegeneration in cerebellar tissues suffering high levels of genotoxic stress [131].
3.4 Radiosensitivity and increased cancer risk
Several DDR pathways contribute to the increased cancer risk seen in A-T 
patients. The inability of A-T cells to coordinate DNA repair with other DDR 
pathways can leave unrepaired genomic injuries and elevate the number of muta-
tions in cells—including perilous DSBs—rendering cells highly sensitive to ionizing 
9The Role of the DNA Damage Response in Ataxia-Telangiectasia Syndrome
DOI: http://dx.doi.org/10.5772/intechopen.84902
radiation. Lack of ATM permits these mutations to escape cell cycle checkpoints 
control and be transmitted to daughter cells, further contributing to tumorigenesis. 
This process can continue unchecked, as the genomic instability that it produces 
does not trigger apoptosis when ATM is absent or dysfunctional.
One of the most common malignancies in A-T patients is breast cancer [132]. 
Even heterozygous individuals bearing debilitating mutations in just one of the 
ATM genes also have increased breast cancer incidence. While many DDR compo-
nents are likely to participate in breast cancer tumorigenesis, the loss of the direct 
control that ATM exerts over BRAC1 is likely one of the major contributing factors. 
Lymphomas of B-cell origin and leukemia of T-cell origin are also very common in 
A-T patients, as unrepaired programmed DSBs persisting in developing T and B cells 
can often be the substrate of translocations [133].
3.5 Other clinical features
Both male and female A-T patients show infertility due to abnormal meiosis 
progression. During meiosis, ATM controls the number of DSBs created by SPO11 
and ensures their even distribution in the genome [134]. This is achieved by recruit-
ing ATM to SPO11-generated DSBs, which inhibits the formation of further cuts in 
the vicinity of break sites. Mice models have shown a meiotic arrest in prophase I, 
faulty synapsis, and chromosome fragmentation leading to massive germ cell loss 
[107, 135], suggesting that the loss of ATM’s roles during meiosis is the underlying 
cause of infertility in A-T patients.
A-T patients can suffer from insulin resistance and thus, have a higher risk of 
developing diabetes, a clinical feature that they share with carriers of the disease. 
The cause for this phenotype is likely to be multifactorial, but it is well-defined 
that ATM phosphorylates several targets—e.g., translation regulation 4E-BP1—in 
response to insulin [25]. Furthermore, a lack of fully functional ATM correlates 
with an inhibition of IRS1 (insulin receptor substrate 1) and low levels of IGF1-R 
(insulin-like growth factor1 receptor), suggesting possible mechanisms causing this 
clinical feature [94, 136, 137].
4. Conclusion
While much progress has been made to understand A-T at the molecular level, 
there are still important questions that remain unanswered. This is especially true for 
the cerebellar neurodegeneration observed in A-T patients, where unknown tissue-
specific factors may be at play. The genesis and the extent of some of the A-T clinical 
features are likely to be the result of interwoven relationships between many path-
ways and pathologies described in here and hence, elucidating their connections will 
be crucial to fully understand the disease and develop effective tools for its treatment.
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